Breaking news

23andMe Files For Chapter 11: Anne Wojcicki Resigns Amid Struggles to Revive Company

by THEFUTURE.TEAM

March 26, 2025

In a bold and unexpected move, 23andMe has filed for Chapter 11 bankruptcy, signaling the company’s struggle to stay afloat amid mounting financial pressure. In its filing with the Eastern District of Missouri federal bankruptcy court, the DNA testing giant revealed it has initiated the process of selling its assets in an attempt to salvage what’s left of its business. Despite the looming uncertainty, 23andMe reassured customers that it would continue operations throughout the asset sale process, emphasizing that there would be no disruptions to how customer data is stored, managed, or protected.

If the bankruptcy court approves its Chapter 11 plan, 23andMe will embark on a 45-day window to solicit bids. If multiple buyers emerge, the company will hold an auction to maximize its value. A key condition for any potential buyer: they must adhere to legal requirements for handling customer data, a significant concern after recent breaches.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

In a related shakeup, co-founder Anne Wojcicki, who once helmed the company, has stepped down as CEO. However, Wojcicki isn’t entirely distancing herself from the company—she will remain on 23andMe’s board and is reportedly preparing to bid on the company’s assets herself. Her resignation follows a failed attempt to take 23andMe private. Last month, she made a bid to acquire the company for $2.53 per share, but the deal collapsed when her partner, New Mountain Capital, pulled out. This was followed by a new bid this month, offering just 41 cents per share—a move swiftly rejected by the company’s board. In a statement on X (formerly Twitter), Wojcicki expressed her disappointment, but also her intent to pursue the company’s assets independently, citing her resignation as a strategic move to position herself better for the bidding process.

The Rise And Fall Of 23andMe

Once a market darling, 23andMe went public in 2021 through a merger with a Special Purpose Acquisition Company (SPAC), reaching a market cap of $6 billion. Wojcicki, a co-founder of the company, saw her fortune soar into the billions. But since then, the company’s stock has plummeted by over 99%, as it failed to reach profitability despite its promising start.

Adding fuel to the fire, the company suffered a major data breach in 2023, when hackers exploited recycled passwords to access sensitive user data. The breach involved over a million genetic data points, including information from high-profile individuals, and was shared across hacker forums. The exposed data included genetic ancestry, birth years, and even personal details of well-known tech figures such as Mark Zuckerberg and Elon Musk. In the aftermath, 23andMe settled in court, agreeing to pay $30 million and offer three years of security monitoring to those affected by the breach.

As 23andMe enters its next phase under bankruptcy proceedings, the company faces a steep uphill battle to regain trust and value. The fate of its assets—and its brand—now rests in the hands of potential buyers.

The Future Forbes Realty Global Properties

Colossal Biosciences Seeks Funding At Up To $30 Billion Valuation

Colossal Biosciences, the biotechnology startup known for its efforts to revive extinct species including the woolly mammoth and dire wolf, is in talks to raise funding at a valuation of $20 billion to $30 billion, according to Axios.

The company was last valued at $10.2 billion in a January funding round. It has since begun generating revenue, Axios reported, although neither the size of the new financing nor its potential investors have been disclosed.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Business Extends Beyond De-Extinction

While Colossal has attracted global attention for its de-extinction projects, the company is also building a broader biotechnology business around the tools developed through that research.

Co-founder and Chief Executive Ben Lamm has said Colossal expects revenue from three areas: conservation technologies, new businesses created from its research and future commercial applications of technologies developed alongside its de-extinction programme.

Expanding Commercial Portfolio

Colossal has already supplied conservation technology to the U.S. government and the United Arab Emirates, which recently invested $60 million in the company, according to Wired.

Its research has also led to the creation of several startups, including plastics recycling company Breaking, computational biology platform Form Bio, which raised $30 million, and AI-driven biology company Astromech, which was valued at $2 billion in March.

Research Continues To Expand

Operating from a 55,000-square-foot facility in Dallas, Colossal continues to broaden its research portfolio.

In April, the company added the bluebuck antelope as its sixth de-extinction target. More recently, the Colossal Foundation partnered with the University of Tasmania to develop vaccines and gene-editing approaches aimed at protecting Tasmanian devils from a contagious facial cancer.

Lamm has also said the company plans to spin out its artificial womb technology, which could eventually have applications in fertility treatment. Speaking to Rolling Stone in May, he said the technology could be ready next year.

Investor Interest In Deep Tech

The fundraising discussions come as investors increase spending on sectors such as biotechnology, longevity and other deep-tech fields.

Lamm has also said Colossal could eventually generate revenue from biodiversity credits if restored species are successfully reintroduced into their natural habitats, creating another potential commercial opportunity.